

Fig. 3 Molecular structural consideration of the W222S mutation of GYG2. **a** Crystal structure of human GYG1 (Protein Data Bank code; 3T7O) (Chaikuad et al. 2011). Each monomer is colored yellow and cyan. α -helices, β -sheet and loops are drawn as ribbons, arrows and threads, respectively. The side chain of W222, glucose and UDP-glucose (UDPG) are shown as sticks in red, orange and green, respectively. Amino acid numbering shown is for human GYG1 with that for human GYG2 in parenthesis. The squared area corresponds to

the close-up views in (b). **b** Detailed views of structures of the wild-type (left) and mutated GYG2 (p.W222S) (right). Amino acid residues at positions of 15, 218 and 220 and UDPG are shown as sticks with van der Waals representation and annotations. Hydrogen bonds are depicted as dotted lines. **c** Calculated free energy change upon the p.W222S mutation of GYG2 using FoldX software. All the molecular structures were drawn using PyMOL (www.pymol.org)

isoform c (NM_001184702), isoform d (NM_001184703), and isoform e (NM_001184704). At least two GYG2 isoforms (isoform a and b) are expressed preferentially in liver, heart and pancreas (Mu et al. 1997), while the detailed expression and function of other isoforms are undetermined. GYG2 has a glycosyltransferase family 8 domain and initiates glucose addition on its Tyrosine residue (Y197 in isoform a) via *O*-glycosylation (self-glycosylation) and can also attach an additional 7–10 residues of UDP-glucose to itself (Bollen et al. 1998; Lomako et al. 2004; Zhai et al. 2001). The W222 within the glycosyltransferase family 8 domain is evolutionarily highly conserved from *S. cerevisiae* to *H. sapiens* (Fig. 1c, d). In addition, all isoforms contain this residue. Thus, it is thought that this mutation may impair its biological function.

Structural consideration of the p.W222S mutation in human GYG2

The amino acid residue W222 of GYG2 (isoform a) was mapped to the crystal structure of human GYG1 (Chaikuad

et al. 2011), since no experimental structure of GYG2 was available. W222 is involved in a hydrophobic core near the UDP-glucose (UDPG) binding site along with Y17 and K220 (Fig. 3a, b). The side chains of Y17 and K220 are hydrogen-bonded to UDPG, and the former also makes van der Waals contacts with the uridine ring of UDPG in a stacking mode. Therefore, the formation of the hydrophobic core appears to be a prerequisite for UDPG binding. To estimate the impact of the W222S mutation on the protein stability, we modeled the mutant structure and calculated the free energy change upon the mutation using the FoldX software. As a result, the mutation was predicted to destabilize the protein structure with about 4 kcal/mol increase in free energy (Fig. 3c). This suggests that the W222S mutation would impair UDPG binding (Fig. 3b).

Self-glycosylation analysis

To see the functional effects of the GYG2 mutation in vitro, glycosyltransferase activity monitoring by self-glycosylation was measured using wild-type (WT) and W222S mutant (Mut) GYG2 (isoform a) transiently




Fig. 4 Enzyme activity of GYG2. **a** Western blot analysis of recombinant GYG2. Wild-type (WT) and mutant (p.W222S) GYG2 was detected at the expected size (52 kDa). β -actin (42 kDa) was used as an internal control. **b** Autoradiography images presenting ¹⁴C glucosylation toward GYG2. The signal was detected in WT, but undetected in mutant, with similar levels to Mock. **c** Graphic presentation of autoglucosylation of GYG2. The activity detected in Mock might be due to the endogenous glycogenin. Error bars represent the standard error of the mean

overexpressed in COS-1 cells. By immunoblotting, the expected 52 kDa bands of recombinant WT and Mut GYG2 were detected with similar expression levels (Fig. 4a). While WT GYG2 showed reasonable glucosyltransferase activity, Mut GYG2 almost completely lost the enzyme activity and was similar to the Mock level (Fig. 4b, c).

Expression analysis of GYG1 and GYG2

To observe tissue distribution of the human *GYG1* and *GYG2*, expression analysis was performed using multiple tissue cDNA panels. *GYG1* was expressed preferentially in skeletal muscle and heart from fetus to adult stages as previous reports (Barbetti et al. 1996). *GYG2* is dominantly expressed in liver from fetus through adult stages and moderately expressed in brain, heart, pancreas and kidney (Supplementary Results, Figure S2). To be marked, *GYG1* is not expressed in liver and brain where *GYG2* is highly expressed.

Discussion

In this study, we analyzed unique brothers affected with LS who were born to non-consanguineous healthy parents after uneventful pregnancies. Patient II-2 and II-3 developed LS accompanied by delayed developmental milestones at 10 months and 13 months of age, respectively. Their age of onset, clinical features and brain imaging were compatible with the diagnosis of LS. Interestingly,

CNS abnormalities were observed (developmental delay, convulsion, athetoid movements, nystagmus, hypotonia, spasticity, increased deep tendon reflex and abnormal reflection), but involvement of peripheral nerve and extra-neural organs was obscure. Based on the facts including (1) male (X-linked recessive), (2) normal lactate/pyruvate, (3) ketonemia/ketonuria, and (4) CNS predominant symptoms, the hemizygous *GYG2* mutation was highlighted a primary culprit.

In this study, we first identified a human *GYG2* mutation in affected brothers with LS with ketonemia/ketonuria but normal blood lactate/pyruvate. We can hypothesize a pathomechanism of the *GYG2* impairment in this family based on the canonical pathway of glycogen metabolism (Fig. 5). As glycogen storage in liver might be decreased because of the *GYG2* malfunction, glucose is easily depleted. To keep appropriate blood glucose concentrations, the metabolism would be shifted toward gluconeogenesis and beta-oxidation to create glucose and energy sources like Acetyl-CoA (Garber et al. 1974; Laffel 1999; Randle et al. 1964). Excess beta-oxidation would result in overproduction of ketone bodies, consistent with the observation of ketonemia and ketonuria. However, pyruvate and lactate could be normally metabolized in gluconeogenesis and/or TCA cycle and would not accumulate in the body as seen in the majority of LS patients. Interestingly, both patients showed normal blood glucose level while showing LS manifestations which might be due to tissue energy depletion. In *GYG2*-deficient patients, the CNS was dominantly affected, while the effect of this abnormal metabolism was thought to extend to the entire body. This predominance could be explained by high glucose consumption as the primary energy source in brain (Amaral 2012; Magistretti and Pellerin 1999) and glycogen depletion in brain tissue level, while the blood sugar level was maintained by the other compensatory mechanism. This is similar to the muscle specific phenotypes (muscle weakness and arrhythmia) observed in patients with deficiencies of “muscle form” *GYG1* in the absence of hypoglycemia (Moslemi et al. 2010). Remarkably, glycogen was less in the muscle tissue of *GYG1* depleted patient (Moslemi et al. 2010). These evidences might indicate that it is not always linked between glucose level in the peripheral blood and glycogen/energy supply in tissue level while we could not show the loss of glycogen in liver or brain tissues because the materials were not available. In addition, deficiencies in two paralogous enzymes, *GYG1* and *GYG2*, result in different human diseases suggesting they are unable to compensate each other in specific organs.

The *GYG2* mutation is probably causative for LS in this family. However, it is possible that the mutation is just coincidence because we just showed genetic evidences (due




Fig. 5 Biochemical metabolisms in glycogen storage and glycolysis pathways. **a** Schematic presentation of glycogen biosynthesis. GYG2 has a catalytic capability for *O*-linked self-glucosylation at Tyrosine (Y197 in isoform a) and adds approximately 10 glucose molecules. By the subsequent elongating reactions by glycogen synthase and branching enzyme, giant molecule “glycogen” is formed. **b** Modeled biochemical pathway in GYG2 impairment. As the GYG2 impairment results in the absence of glycogen storage, glycogen is easy to be depleted and gluconeogenesis is induced from fat tissues and

glucogenic amino acids. The reactions in mitochondria are shown in *yellow shadow*. While increased acetyl-CoA inhibits the pyruvate dehydrogenase complex which irreversibly converts pyruvate to acetyl-CoA (as shown as *dotted line*), it accelerates gluconeogenesis through pyruvate–oxaloacetic acid–malic acid–oxaloacetic acid. Triacylglycerol was metabolized into glycerin and fatty acid. Fatty acid was used for beta-oxidation and ketone production. The *arrows* indicate the directions of normal metabolism. *Red arrows* indicate the predicted predominant pathways in GYG2-deficient patients

to its rarity and familial co-segregation) and GYG2 loss of function by *in vitro* study without showing any sufficient data on how the GYG2 mutation causes LS.

In conclusion, we describe the first human variant of GYG2 which may be associated with the atypical LS phenotype in this family. Further studies are absolutely needed to conclude whether GYG2 abnormality leads to atypical LS observed in this family.

Acknowledgments We thank all the patients and their families for participating in this work. We deeply appreciate Dr. Toshiyuki Fukao, who is the professor of Department of Pediatrics, Graduate School of Medicine, Gifu University, for the enzyme assay for 3-ketothiolase deficiency and succinyl-CoA:3-oxoacid CoA transferase. We would like to thank Dr. Yasushi Okazaki at Research Center for Genomic Medicine, Saitama Medical University for helpful discussion. We also

thank Ms. Y. Yamashita, S. Sugimoto and K. Takabe for their technical assistance. This work was supported by research grants from the Ministry of Health, Labour, and Welfare (H. Saitsu, N. Matsumoto and N. Miyake), the Japan Science and Technology Agency (N. Matsumoto), the Strategic Research Program for Brain Sciences (to N. Matsumoto), a Grant-in-Aid for Scientific Research on Innovative Areas (Transcription Cycle) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (N. Matsumoto), a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (to N. Matsumoto), a Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science (H. Saitsu and N. Miyake), a grant from the 2012 Strategic Research Promotion of Yokohama City University (N. Matsumoto), and research grants from the Japan Epilepsy Research Foundation (H. Saitsu) and the Takeda Science Foundation (N. Matsumoto and N. Miyake).

Conflict of interest The authors declare that they have no conflict of interest.

References

- Amaral AI (2012) Effects of hypoglycaemia on neuronal metabolism in the adult brain: role of alternative substrates to glucose. *J Inher Metab Dis*. doi:10.1007/s10545-012-9553-3
- Antonicka H, Ostergaard E, Sasarman F, Weraarpachai W, Wibrand F, Pedersen AM, Rodenburg RJ, van der Knaap MS, Smeitink JA, Chrzanowska-Lightowlers ZM, Shoubbridge EA (2010) Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. *Am J Hum Genet* 87:115–122. doi:10.1016/j.ajhg.2010.06.004
- Barbetti F, Rocchi M, Bossolasco M, Cordera R, Sbraccia P, Finelli P, Consalez GG (1996) The human skeletal muscle glycogenin gene: cDNA, tissue expression and chromosomal localization. *Biochem Biophys Res Commun* 220:72–77. doi:10.1006/bbrc.1996.0359
- Benke PJ, Parker JC Jr, Lubs ML, Benkendorf J, Feuer AE (1982) X-linked Leigh's syndrome. *Hum Genet* 62:52–59
- Bollen M, Keppens S, Stalmans W (1998) Specific features of glycogen metabolism in the liver. *Biochem J* 336:19–31
- Brown GK, Squier MV (1996) Neuropathology and pathogenesis of mitochondrial diseases. *J Inher Metab Dis* 19:553–572
- Cao Y, Mahrenholz AM, DePaoli-Roach AA, Roach PJ (1993) Characterization of rabbit skeletal muscle glycogenin. Tyrosine 194 is essential for function. *J Biol Chem* 268:14687–14693
- Chaikuad A, Froese DS, Berridge G, von Delft F, Oppermann U, Yue WW (2011) Conformational plasticity of glycogenin and its maltosaccharide substrate during glycogen biogenesis. *Proc Natl Acad Sci USA* 108:21028–21033. doi:10.1073/pnas.1113921108
- Debray FG, Morin C, Janvier A, Villeneuve J, Maranda B, Laframboise R, Lacroix J, Decarie JC, Robitaille Y, Lambert M, Robinson BH, Mitchell GA (2011) LRPPRC mutations cause a phenotypically distinct form of Leigh syndrome with cytochrome c oxidase deficiency. *J Med Genet* 48:183–189. doi:10.1136/jmg.2010.081976
- Farina L, Chiapparini L, Uziel G, Bugiani M, Zeviani M, Savoirdo M (2002) MR findings in Leigh syndrome with COX deficiency and SURF-1 mutations. *AJNR Am J Neuroradiol* 23:1095–1100
- Finsterer J (2008) Leigh and Leigh-like syndrome in children and adults. *Pediatr Neurol* 39:223–235. doi:10.1016/j.pediatrneurol.2008.07.013
- Garber AJ, Menzel PH, Boden G, Owen OE (1974) Hepatic ketogenesis and gluconeogenesis in humans. *J Clin Invest* 54:981–989. doi:10.1172/JCI107839
- Gibbons BJ, Roach PJ, Hurley TD (2002) Crystal structure of the autocatalytic initiator of glycogen biosynthesis, glycogenin. *J Mol Biol* 319:463–477. doi:10.1016/S0022-2836(02)00305-4
- Guerois R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. *J Mol Biol* 320:369–387. doi:10.1016/S0022-2836(02)00442-4
- Khan S, Vihinen M (2010) Performance of protein stability predictors. *Hum Mutat* 31:675–684. doi:10.1002/humu.21242
- Krisman CR, Barengo R (1975) A precursor of glycogen biosynthesis: alpha-1,4-glycan-protein. *Eur J Biochem* 52:117–123
- Laffel L (1999) Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. *Diabetes Metab Res Rev* 15:412–426
- Larner J (1953) The action of branching enzymes on outer chains of glycogen. *J Biol Chem* 202:491–503
- Leigh D (1951) Subacute necrotizing encephalomyelopathy in an infant. *J Neurol Neurosurg Psychiatry* 14:216–221
- Lomako J, Lomako WM, Whelan WJ (1988) A self-glucosylating protein is the primer for rabbit muscle glycogen biosynthesis. *FASEB J* 2:3097–3103
- Lomako J, Lomako WM, Whelan WJ (2004) Glycogenin: the primer for mammalian and yeast glycogen synthesis. *Biochim Biophys Acta* 1673:45–55. doi:10.1016/j.bbagen.2004.03.017
- Lopez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, Dimauro S, Hirano M (2006) Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. *Am J Hum Genet* 79:1125–1129. doi:10.1086/510023
- Magistretti PJ, Pellerin L (1999) Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. *Philos Trans R Soc Lond B Biol Sci* 354:1155–1163. doi:10.1098/rstb.1999.0471
- Martin MA, Blazquez A, Gutierrez-Solana LG, Fernandez-Moreira D, Briones P, Andreu AL, Garesse R, Campos Y, Arenas J (2005) Leigh syndrome associated with mitochondrial complex I deficiency due to a novel mutation in the NDUFS1 gene. *Arch Neurol* 62:659–661. doi:10.1001/archneur.62.4.659
- Medina L, Chi TL, DeVivo DC, Hilal SK (1990) MR findings in patients with subacute necrotizing encephalomyelopathy (Leigh syndrome): correlation with biochemical defect. *AJR Am J Roentgenol* 154:1269–1274
- Moslemi AR, Lindberg C, Nilsson J, Tajsharghi H, Andersson B, Oldfors A (2010) Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. *N Engl J Med* 362:1203–1210. doi:10.1056/NEJMoa0900661
- Mu J, Roach PJ (1998) Characterization of human glycogenin-2, a self-glucosylating initiator of liver glycogen metabolism. *J Biol Chem* 273:34850–34856
- Mu J, Skurat AV, Roach PJ (1997) Glycogenin-2, a novel self-glucosylating protein involved in liver glycogen biosynthesis. *J Biol Chem* 272:27589–27597
- Naess K, Freyer C, Bruhn H, Wibom R, Malm G, Nennesmo I, von Döbeln U, Larsson NG (2009) MtDNA mutations are a common cause of severe disease phenotypes in children with Leigh syndrome. *Biochim Biophys Acta* 1787:484–490. doi:10.1016/j.bbabi.2008.11.014
- Ostergaard E, Hansen FJ, Sorensen N, Duno M, Vissing J, Larsen PL, Faeroe O, Thorgrimsson S, Wibrand F, Christensen E, Schwartz M (2007) Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. *Brain* 130:853–861. doi:10.1093/brain/awl383
- Picardi E, Pesole G (2012) Mitochondrial genomes gleaned from human whole-exome sequencing. *Nat Methods* 9:523–524. doi:10.1038/nmeth.2029
- Pitcher J, Smythe C, Cohen P (1988) Glycogenin is the priming glucosyltransferase required for the initiation of glycogen biogenesis in rabbit skeletal muscle. *Eur J Biochem* 176:391–395
- Quinonez SC, Leber SM, Martin DM, Thoene JG, Bedoyan JK (2013) Leigh syndrome in a girl with a novel DLD mutation causing E3 deficiency. *Pediatr Neurol* 48:67–72. doi:10.1016/j.pediatrneurol.2012.09.013
- Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR (1996) Leigh syndrome: clinical features and biochemical and DNA abnormalities. *Ann Neurol* 39:343–351. doi:10.1002/ana.410390311
- Randle PJ, Newsholme EA, Garland PB (1964) Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. *Biochem J* 93:652–665
- Smythe C, Caudwell FB, Ferguson M, Cohen P (1988) Isolation and structural analysis of a peptide containing the novel tyrosyl-glucose linkage in glycogenin. *EMBO J* 7:2681–2686
- van Erven PM, Cillessen JP, Eekhoff EM, Gabreels FJ, Doesburg WH, Lemmens WA, Slooff JL, Renier WO, Ruitenbeek W (1987)

- Leigh syndrome, a mitochondrial encephalo(myo)pathy. A review of the literature. *Clin Neurol Neurosurg* 89:217–230
- Viskupic E, Cao Y, Zhang W, Cheng C, DePaoli-Roach AA, Roach PJ (1992) Rabbit skeletal muscle glycogenin. Molecular cloning and production of fully functional protein in *Escherichia coli*. *J Biol Chem* 267:25759–25763
- Zhai L, Schroeder J, Skurat AV, Roach PJ (2001) Do rodents have a gene encoding glycogenin-2, the liver isoform of the self-glucosylating initiator of glycogen synthesis? *IUBMB Life* 51:87–91. doi:10.1080/15216540117315

Brachial plexus MRI showed increased signal intensity with contrast enhancement of the right long thoracic nerve, suggesting inflammation (Fig. 1). The patient was given oral prednisolone, 1 mg/kg daily for 21 days, with dose tapering over the next month. Three months later, her symptoms were stable, but electrophysiological follow-up showed a slight reduction of fibrillation potentials in right serratus anterior muscle.

Scapular winging is caused by imbalanced action of scapular muscles. The clinical examination based on the muscle group affected (trapezius, rhomboids, serratus anterior) is still the first guide for interpretation both of "pure" and "complicated" phenotypes.¹ Isolated scapular winging due to serratus anterior weakness is usually caused by traumatic or postsurgical long thoracic nerve injury, or it can occur as a manifestation of neuralgic amyotrophy, also known as Parsonage-Turner syndrome (PTS). PTS is a clinical syndrome characterized by attacks of extreme pain at onset, patchy weakness in the upper extremities, and atrophy of affected muscles.²

The available evidence suggests that PTS has a complex pathophysiology that includes an underlying predisposition, susceptibility to dysfunction of some peripheral nervous system structures, and an autoimmune trigger.³ Cases of PTS are described after an immune event, such as pregnancy, childbirth, vaccination, or infection.²

Our patient did not have a history of previous surgery or trauma involving the thoracic area. Other possible causes were excluded by the laboratory evaluation. Moreover, she did not experience acute pain at onset, but only subsequent musculoskeletal pain due to compensation for the deficit. Since childbirth, an immunological trigger, occurred 3 days before symptom onset and approximately 4% of patients with PTS do not experience pain,² we made a diagnosis of post-partum PTS.

Currently, neuralgic amyotrophy cannot be diagnosed confidently by a single test, and often the presence of extreme pain of the upper limb together with patchy paresis helps in the diagnosis. In PTS without pain at onset, neuroimaging studies can be very useful, because they can exclude other causes such as intervertebral disc disease, tumors, or entrapment neuropathies. Furthermore, the evidence of contrast enhancement on MRI suggests a possible inflammatory etiology, thus supporting early administration of corticosteroids even in absence of pain, to block further evolution of the clinical picture and to possibly speed up functional nerve recovery.

In conclusion, contrast-enhanced MRI can provide crucial help in identifying different phenotypes of PTS and can guide therapy.

Viviana Nociti, MD, PhD¹

Mauro Monforte, MD,²

Alessia Perna, MD²

Francesca Madia, MD, PhD²

Giovanni Melchiorri, MD³

Massimiliano Mirabella, MD, PhD²

¹Don Carlo Gnocchi Onlus Foundation, Milan, Italy

²Institute of Neurology, Catholic University, Rome, Italy

³Motor Science Degree, Tor Vergata University, Rome, Italy

1. Monforte M, Ricci E, Iannaccone E, Tasca G. Teaching Video Neuro-Images: Complicated scapular winging. *Neurology* 2013;81:e95.
2. van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. *Nat Rev Neurol* 2011;7:315-322.
3. van Alfen N. The neuralgic amyotrophy consultation. *J Neurol* 2007; 254:695-704.

Published online 13 September 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mus.24073

A PRIMIGRAVIDA WITH VERY-LONG-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY

We report a woman who had the adult-onset form of very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency^{1,2} and developed acute postpartum heart failure due to cardiomyopathy.

A 34-year-old primigravida visited our clinic due to nocturnal dyspnea. She had suffered from exercise-induced muscle pain since she was 5 years of age. Her food intake was insufficient due to hyperemesis gravidarum, and she developed severe generalized myalgia at 14 weeks' gestation. Her serum creatine kinase was 21,530 IU/L, and myoglobinuria was detected. From 15-30 weeks' gestation, her appetite recovered, and frequency of myalgia decreased. She delivered a baby by Caesarean section at 37 weeks without any complications.

She was transferred to our hospital on postpartum day 10 for treatment of heart failure. Serum glucose, creatine kinase, lactate, pyruvate, ammonia, and cardiac troponin T were within the normal ranges, but brain natriuretic peptide was increased to 3194.5 pg/ml. The left ventricular ejection fraction on echocardiography was 30%. Furosemide and carperitide were administered intravenously, and oral losartan and carvedilol were started on day 6 after admission. Sixty days after admission, echocardiography revealed no pericardial effusion and normal movement of the basal portion of the septum without any medications. There was no muscle weakness during or after pregnancy.

A muscle biopsy showed only mild fiber size variation without pathological findings. We measured acyl-CoA dehydrogenase activities using frozen muscle biopsy specimens.³ Palmitoyl-CoA activity was reduced

Table 1. Results of β -oxidation enzyme analysis.

	Patient	Controls
Camitine (free)	3.7	12.9 \pm 3.7
Camitine (total)	5.8	15.7 \pm 2.8
Camitine palmytoyl transferase II	0.9	1.6 \pm 0.4
Acyl-CoA-dehydrogenase (substrate: C16:0)	4.1	24.5 \pm 6.1
Acyl-CoA-dehydrogenase (substrate: C8:0)	6.1	8.1 \pm 2.5
Acyl-CoA-dehydrogenase (substrate: C4:0)	15.7	16.8 \pm 3.9
C16:0/C8:0	0.7	3.8 \pm 1.4
C16:0/C4:0	0.3	1.8 \pm 0.2
C8:0/C4:0	0.4	0.5 \pm 0.1

compared with normal controls, but octanoyl-CoA activity was within the normal range (Table 1).

We sequenced the acyl-CoA dehydrogenase (very-long-chain) (*ACADVL*) gene in both the patient and controls.^{4,5} DNA was extracted from muscle biopsy specimens using conventional methods. Sequence analysis of *ACADVL* revealed a novel homozygous c.272C>T mutation (p.P91L).

Patients with missense mutations or single amino acid deletions in the adult-onset form of VLCAD deficiency show energy deficiency and exercise-induced rhabdomyolysis or myoglobinuria.^{6,7} During early pregnancy, our patient was malnourished due to hyperemesis gravidarum and suffered severe myalgia and rhabdomyolysis. She also developed acute heart failure at 2 weeks postpartum. She lacked the capacity for proper fatty acid oxidation and was in a catabolic state. In addition to a poor nutritional state, delivery may have served as a trigger for acute energy failure.

The nature of heart failure in our patient is quite different from that of rhabdomyolysis. Because Ca^{2+} homeostasis is altered in the VLCAD^{-/-} mouse heart, abnormal intracellular Ca^{2+} handling can cause arrhythmias and lethal cardiac failure.⁸ The accumulation of long-chain acylcarnitines in the heart has been shown to lead to cardiomyopathy and arrhythmia due to calcium uncoupling disorders.⁹ Although cardiomyopathy has been reported in the childhood form of severe VLCAD deficiency,¹⁰ 13% of patients with adult-onset VLCAD deficiency also develop cardiomyopathy.^{6,11} Unlike the childhood form, patients with the adult-onset form due to missense mutations or single amino acid deletions have slight residual VLCAD activity and can avoid severe heart failure when treated with medium-chain triglycerides as the major source of dietary fat.^{12,13} VLCAD deficiency should be included in the differential diagnosis of acute postpartum cardiomyopathy.

Ken-ya Murata, MD, PhD¹

Hideo Sugie, MD, PhD²

Ichizo Nishino, MD, PhD³

Tomoyoshi Kondo, MD, PhD¹

Hidefumi Ito, MD, PhD¹

¹Department of Neurology, Wakayama Medical University, Wakayama, Japan

²Department of Pediatrics, Jichi Medical University, Tochigi, Japan

³Department of Neuromuscular Research, National Institute of Neuroscience, National Center for Neurology and Psychiatry, Tokyo, Japan

1. Pons R, Cavadini P, Baratta S, Invernizzi F, Lamantea E, Garavaglia B, et al. Clinical and molecular heterogeneity in very-long-chain acyl-coenzyme A dehydrogenase deficiency. *Pediatr Neurol* 2000;22:98–105.
2. Iwai K, Uchida Y, Orii T, Yamamoto S, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase. *J Biol Chem* 1992;267:1027–1033.
3. Verity MA, Turnbull DM. Assay of acyl-CoA dehydrogenase activity in frozen muscle biopsies: application to medium-chain acyl-CoA dehydrogenase deficiency. *Biochem Med Metab Biol* 1993;49:351–362.
4. Andresen BS, Bross P, Vianey-Saban C, Divry P, Zabot MT, Roe CR, et al. Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. *Hum Mol Genet* 1996;5:461–472.
5. Orii KO, Aoyama T, Souri M, Orii KE, Kondo N, Orii T, et al. Genomic DNA organization of human mitochondrial very-long-chain acyl-CoA dehydrogenase and mutation analysis. *Biochem Biophys Res Commun* 1995;217:987–992.
6. Andresen BS, Olpin S, Poorthuis BJ, Scholte HR, Vianey-Saban C, Wanders R, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. *Am J Hum Genet* 1999;64:479–494.
7. Orngreen MC, Norgaard MG, Sacchetti M, van Engelen BG, Vissing J. Fuel utilization in patients with very long-chain acyl-CoA dehydrogenase deficiency. *Ann Neurol* 2004;56:279–283.
8. Werdich AA, Baudenbacher F, Dzura J, Jeyakumar LJI, Kannankeril PJ, Fleischer S, et al. Polymorphic ventricular tachycardia and abnormal Ca^{2+} handling in very-long-chain acyl-CoA dehydrogenase null mice. *Am J Physiol Heart Circ Physiol* 2007;292:H2202–2211.
9. Yamada KA, McIlwain J, Yan GX, Donahue K, Peirick J, Kleber AG, et al. Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia. *Circ Res* 1994;74:83–95.
10. Yamaguchi S, Indo Y, Coates PM, Hashimoto T, Tanaka K. Identification of very-long-chain acyl-CoA dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. *Pediatr Res* 1998;34:111–113.
11. Parini R, Menni F, Garavaglia B, Fesslova V, Melotti D, Massone ML, et al. Acute, severe cardiomyopathy as main symptom of late-onset very long-chain acyl-coenzyme A dehydrogenase deficiency. *Eur J Pediatr* 1998;157:992–995.
12. Brown-Harrison MC, Nada MA, Sprecher II, Vianey-Saban C, Farquhar J Jr, Gilladoga AC, et al. Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. *Biochem Mol Med* 1996;58:59–65.
13. Bhattacharyya A, Basra SS, Sen P, Kar B. Peripartum cardiomyopathy: a review. *Tex Heart Inst J* 2012;39:8–16.

Published online 22 August 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mus.24055

Case report

Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology

Rie S. Tsuburaya^{a,b}, Kazunari Monma^a, Yasushi Oya^a, Takahiro Nakayama^c, Tokiko Fukuda^d, Hideo Sugie^d, Yukiko K. Hayashi^a, Ikuya Nonaka^a, Ichizo Nishino^{a,*}

^a Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan

^b Department of Pediatrics, Tohoku University School of Medicine, Miyagi, Japan

^c Department of Neurology, Yokohama Rosai Hospital, Kanagawa, Japan

^d Department of Pediatrics, Jichi Medical University and Jichi Children's Medical Center, Tochigi, Japan

Received 18 August 2011; received in revised form 19 October 2011; accepted 15 November 2011

Abstract

Diagnosis of adult-onset Pompe disease is sometimes challenging because of its clinical similarities to muscular dystrophy and the paucity of disease-specific vacuolated fibers in the skeletal muscle pathology. We describe two patients with adult-onset Pompe disease whose muscle pathology showed no typical vacuolated fibers but did show unique globular inclusions with acid phosphatase activity. The acid phosphatase-positive globular inclusions may be a useful diagnostic marker for adult-onset Pompe disease even when typical vacuolated fibers are absent.

© 2011 Elsevier B.V. All rights reserved.

Keywords: Pompe disease; GAA; Globular inclusion; Acid phosphatase

1. Introduction

Pompe disease (glycogen storage disease type 2; acid maltase deficiency; OMIM #232300) is an autosomal recessive disease caused by mutations in the gene encoding acid α -glucosidase (GAA, OMIM #606800), a lysosomal enzyme involved in glycogen degradation [1]. Based on age of onset and clinical severity, which depends on residual GAA activity, the disease can be classified into infantile, childhood-onset, and adult-onset forms.

Most of the infantile and childhood-onset forms exhibit disease-specific skeletal muscle pathology, which shows fibers occupied by huge vacuoles that contain basophilic amorphous materials. However, diagnosis of the adult-onset form is sometimes challenging due to clinical similarities to muscular dystrophy and the paucity of typical vacuolated myofibers. We diagnosed 37 patients with Pompe disease including 11 infantile, 16 childhood-onset, and 10 adult-onset forms in the muscle repository of the National Center of Neurology and Psychiatry (NCNP), Japan, based on a deficiency of GAA enzyme activity assayed using biopsied muscles, as previously described [2]. Among these 37 patients, two unrelated Japanese patients did not have disease-specific vacuolated muscle fibers but did have unique cytoplasmic inclusions. Here, we report the diagnostic utility of acid phosphatase (ACP)-positive globular inclusions for adult-onset Pompe disease.

* Corresponding author. Address: National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8502, Japan. Tel.: +81 42 341 2711; fax: +81 42 346 1742.

E-mail address: nishino@ncnp.go.jp (I. Nishino).

2. Case report

2.1. Clinical summary

Patient 1: A 44-year-old man had been well until the age of 41 years when he started having difficulty in running. He was admitted to the hospital because of progressive muscle weakness. His parents were first cousins, but there was no family history of neuromuscular disorders. He was clinically suspected to suffer from muscular dystrophy because of slowly progressive muscle weakness and elevated creatine kinase levels of around 800 IU/L (normal, <171 IU/L). On examination, he had grade 4-muscle weakness on medical research council (MRC) scale and marked atrophy in his thighs. He did not have apparent respiratory impairment. Electromyography (EMG) showed myopathic changes with fibrillation and increased polyphasic motor unit potentials (MUPs).

Patient 2: A 62-year-old woman first noticed difficulty in climbing stairs at the age of 35 years, and needed a stick to walk at 45 years. Muscle weakness gradually worsened predominantly in her proximal limbs, and she became wheelchair-bound at 55 years. A muscle biopsy was performed at the age of 61 years. On examination, she had muscle weakness and atrophy predominantly in the proximal upper and lower limbs at the grade 3–4 on MRC scale. Serum CK level was 70 IU/L (normal, <142 IU/L). An EMG showed myopathic changes with increased polyphasic MUPs and myotonic-like repetitive discharges. She had been on non-invasive positive-pressure ventilation since the age of 62 years when the respiratory insufficiency appeared.

2.2. Skeletal muscle pathology

The skeletal muscle pathology from the vastus lateralis of patient 1 and from the biceps brachii of patient 2 showed nonspecific myopathic changes with moderate fiber size variation, mild endomysial fibrosis, and some fiber splitting (Fig. 1A). No necrotic or regenerating fibers were seen. No vacuoles containing amorphous materials were observed. Importantly, both muscles contained red–purple globular inclusions on modified Gomori-trichrome (mGT) stain (Fig. 1A and B). The average percentages of fibers with globular inclusions in the whole mGT-stained section were 0.5% in patient 1 and 2% in patient 2. These inclusions were invariably highlighted by ACP stain but not stained by periodic acid Schiff (PAS) (Fig. 1C). Inclusions were stained only faintly on menadione-linked α -glycerophosphate dehydrogenase (MAG) without substrate (Fig. 3A). Fibers with ACP-positive globular inclusions were also found in 15 of 16 childhood-onset and seven of eight adult-onset patients with disease-specific pathology in varying proportions (0.1–10%). The rate of fibers with inclusions was not significantly different between the childhood-onset and adult-onset forms. Fibers carrying inclusions did not have typical vacuoles with amorphous materials inside. In the infantile cases, more than 90% of

the fibers were vacuolated, whereas non-vacuolated fibers with inclusions were hardly recognizable.

Double immunostaining was performed using primary antibodies against a lysosomal marker, lysosomal associated membrane protein-2 (LAMP-2; Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA, USA) and an autophagosomal marker, microtubule-associated protein 1 light chain 3 (LC3; Novus Biologicals, Littleton, CO, USA). In fibers with ACP-positive inclusions, immunoreactivity for LAMP-2 and LC3 were accumulated focally in inclusions and surrounding area (Fig. 1D). We also examined another samples from adult-onset patients with typical vacuoles. Fibers with typical vacuoles were entirely positive for LAMP-2 and LC3 (data not shown).

On PAS staining, performed on epon-embedded sections (Epon-PAS) to detect glycogen more sensitively, PAS was negative in globular inclusions but positive in the surrounding area (Fig. 1E).

Electron micrography was performed as previously described using a Tecnai spirit transmission electron microscope (FEI, Hillsboro, OR, USA) [3]. The inclusions consisted of homogeneous electron-dense globules surrounded by increased glycogen particles and autophagic vacuoles (Fig. 1F). The globules contained neither dotted glycogen particles nor a filamentous structure.

2.3. GAA enzymatic analysis and genetic analysis

Presence of globular inclusions led us to suspect Pompe disease, and GAA enzymatic activity analyses revealed 7.5% of normal control activity in patient 1 and 12.3% in patient 2.

Genomic DNA was extracted from peripheral lymphocytes or biopsied muscle using a standard protocol for mutational analysis of *GAA*. All exons and their flanking intronic regions of *GAA* were amplified by PCR and directly sequenced with an ABI PRISM 3100 Automated Sequencer (Applied Biosystems, Foster City, CA, USA). Both patients carried the homozygous *GAA* mutation at the last codon of exon 2 (c. 546G > T). RT-PCR and direct sequencing were performed using RNA extracted from biopsied muscles. This novel mutation causes aberrant splicing by skipping exon 2 (Fig. 2). This homozygous c. 546G > T mutation was also found in another patient with the adult-onset form, whose muscle pathology showed typical skeletal muscle pathology with vacuolated fibers.

3. Discussion

ACP-positive globular inclusions were a good diagnostic marker for the two patients with adult-onset Pompe disease lacking typical vacuolated fibers. Among 12,103 muscle biopsies in the NCNP repository from 1979 to 2010, ACP-positive globular inclusions were not reported, except for Pompe disease.

The globular inclusions are most likely the same as “reducing body-like globular inclusions in late-onset Pompe disease” reported by Sharma et al., as the pathological features are




Fig. 1. Acid phosphatase-positive globular inclusions in patient 2. (A and B) Biopsied skeletal muscle showed nonspecific myopathic changes with scattered red–purple colored globular inclusions on modified Gomori-trichrome stain. (C) The inclusions have intense activity on acid phosphatase stain. Bar = 20 μ m. (D) Double immunostaining for LAMP-2 (green) and LC3 (red) demonstrates colocalization of positive immunoreactions in the inclusions and surrounding area (B–D; serial sections). (E) On epon-embedded section, periodic acid Schiff stain is negative in inclusions (arrows). Bar = 5 μ m. (F) On electron microscopy, globular inclusions (asterisks) lack Z-line structure, which differs from cytoplasmic bodies. Autophagic vacuoles (arrows) and glycogen particles (arrow heads) are seen in the vicinity of globular inclusions (12000 \times).




Fig. 2. Mutational analysis of *GAA*. Both patient have a homozygous c. 546G > T mutation at the last codon of exon2 (A upper: control, lower: patient), which creates mRNA with skipping exon 2 (B).




Fig. 3. Inclusions on menadione-linked α -glycerophosphate dehydrogenase (MAG) without substrate. Globular inclusions in Pompe disease (A) are only faintly stained comparing reducing bodies in reducing body myopathy with *FHL1* mutation (B). Bar = 20 μ m.

rather similar [4]. However, globular inclusions showed much fainter staining on MAG without substrate than genuine reducing bodies seen in reducing body myopathy with *FHL1* mutations (Fig. 3). More importantly, ACP positivity has not been clearly described previously.

These globular inclusions are reminiscent of cytoplasmic bodies, which are nonspecific findings reflecting degeneration of the Z-disk in various neuromuscular diseases, particularly myofibrillar myopathies. However, the nature of the globular inclusions differs essentially from cytoplasmic bodies because of positive ACP staining and the lack of associated Z-disk components. Although it remains unclear how the ACP-positive globular inclusions are formed, the absence of glycogens in the globular inclusions suggest that they differ from glycogen accumulations in lysosomes. Fibers with typical vacuoles were diffusely positive for both lysosomal and autophagosomal markers as shown previously [5,6]. On the other hand, immunoreactivities of these markers accumulated more focally in fibers with inclusions. Further study should be needed to clarify what causes these pathological differences.

In conclusion, ACP-positive globular inclusions may be a hallmark of Pompe disease and a useful diagnostic marker

for adult-onset Pompe disease lacking typical vacuolated fibers. Since enzyme replacement therapy is effective, albeit not fully, in adult-onset patients, early diagnosis is necessary for a better prognosis.

Ethical approval

All clinical materials used in this study were obtained for diagnostic purposes with written informed consent approved by the Ethical Committee of NCNP.

Acknowledgements

We are grateful to Satomi Mitsuhashi, Kaoru Tatezawa, Yuriko Kure, Mieko Ohnishi, and Kanako Goto (NCNP) for their technical assistance, to May Christine V. Malicdan (National Human Genome Research Institute, National Institutes of Health) for reviewing the manuscript. This study was supported by: a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science; Research on Psychiatric and Neurological Diseases and Mental Health, Research on Measures for Intractable Diseases, Health Labor Sciences Research

Grant for Nervous and Mental Disorders (20B-12, 20B-13) from the Ministry of Health, Labor, and Welfare, and Intramural Research Grant (23-4, 23-5) for Neurological and Psychiatric Disorders from NCNP.

References

- [1] Hers HG. Alpha-glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). *Biochem J* 1963;86:11–6.
- [2] Shanske S, Dimauro S. Late-onset acid maltase deficiency. Biochemical studies of leukocytes. *J Neurol Sci* 1981;50:57–62.
- [3] Park YE, Hayashi YK, Goto K, et al. Nuclear changes in skeletal muscle extend to satellite cells in autosomal dominant Emery-Dreifuss muscular dystrophy/limb-girdle muscular dystrophy 1B. *Neuromuscul Disord* 2009;19:29–36.
- [4] Sharma MC, Schultze C, von Moers A, et al. Delayed or late-onset type II glycogenosis with globular inclusions. *Acta Neuropathol* 2005;110:151–7.
- [5] Raben N, Ralston E, Chien YH, et al. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. *Mol Genet Metab* 2010;101:324–31.
- [6] Schoser BGH, Müller-Höcker J, Horvath R, et al. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. *Neuropathol Appl Neurobiol* 2007;33:544–59.

Case report

Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia

Sayuri Sukigara^a, Wen-Chen Liang^{b,c}, Hirofumi Komaki^a, Tokiko Fukuda^d,
Takeshi Miyamoto^c, Takashi Saito^a, Yoshiaki Saito^a, Eiji Nakagawa^a, Kenji Sugai^a,
Yukiko K. Hayashi^b, Hideo Sugie^d, Masayuki Sasaki^a, Ichizo Nishino^{b,*}

^a Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry (NCNP), Kodaira, Tokyo, Japan

^b Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, Kodaira, Tokyo, Japan

^c Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

^d Department of Pediatrics, Jichi Medical University and Jichi Children's Medical Center, Shimotsuke, Tochigi, Japan

^e Department of Pediatrics, Kosai Municipal Hospital, Kosai, Shizuoka, Japan

Received 22 March 2011; received in revised form 17 June 2011; accepted 22 August 2011

Abstract

Muscle glycogen storage disease 0 (GSD0) is caused by glycogen depletion in skeletal and cardiac muscles due to deficiency of glycogen synthase 1 (GYS1), which is encoded by the *GYS1* gene. Only two families with this disease have been identified. We report a new muscle GSD0 patient, a Japanese girl, who had been suffering from recurrent attacks of exertional syncope accompanied by muscle weakness and pain since age 5 years until she died of cardiac arrest at age 12. Muscle biopsy at age 11 years showed glycogen depletion in all muscle fibers. Her loss of consciousness was gradual and lasted for hours, suggesting that the syncope may not be simply caused by cardiac event but probably also contributed by metabolic distress.

© 2011 Elsevier B.V. All rights reserved.

Keywords: Glycogen storage disease; Glycogen synthase; Glycogen; Syncope; Sudden death

1. Introduction

Glycogen is a high molecular mass polysaccharide that serves as a repository of glucose for use in times of metabolic need. It is stored in liver, cardiac and skeletal muscles, and broken down to glucose to produce ATP as energy as needed. For the synthesis of glycogen, at least two proteins, glycogenin (GYG) and glycogen synthase (GYS), are known to be essential. GYG is involved in the initiation reactions of glycogen synthesis: the covalent attachment of a glucose residue to GYG is followed by elongation to

form an oligosaccharide chain [1]. GYS catalyzes the addition of glucose monomers to the growing glycogen molecule through the formation of alpha-1,4-glycoside linkages [2].

Defect in either GYG or GYS can cause glycogen depletion. Recently, muscle glycogen deficiency due to a mutation in a gene encoding muscle GYG, *GYG1*, was reported [3] and named as glycogen storage disease type XV. In contrast, glycogen depletion caused by the *GYS* gene mutation is called glycogen storage disease type 0 (GSD0). GSD0 was first reported in 1990 in patients with type 2 diabetes who had a defect in glycogen synthesis in liver, which was caused by a defect in liver GYS, *GYS2*, and the disease was named as liver GSD0 (or also called GSD0a) [4,5].

The disease of muscle GYS, *GYS1*, was first described in 2007 in three siblings and named muscle GSD0, which is

* Corresponding author. Address: Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, 4-1-1, Ogawahigashi-cho, Kodaira, Tokyo 187 8551, Japan. Tel.: +81 42 3412711; fax: +81 42 3427521.

E-mail address: nishino@ncnp.go.jp (I. Nishino).

also called GSD0b [6]. One of the patients initially manifested exercise intolerance, epilepsy and long QT syndrome since the age of 4 years, then died of sudden cardiac arrest after exertion when he was 10.5-year-old. The other two siblings were then genetically confirmed as muscle GSD0 with mutations in *GYS1* and cardiac involvement was also found in both. The second muscle GSD0 family was reported in 2009 [7]. The 8-year-old boy had been healthy before collapsing during a bout of exercise, resulting in death. Post-mortem examinations and studies verified the diagnosis of muscle GSD0. He had a female sibling who died at 6 days of age of undetermined cause. Here we report the first muscle GSD0 patient in Asia with some distinct clinical manifestations from other reported cases.

2. Case report

An 11-year-old Japanese girl with repeated episodes of post-exercise loss of consciousness, weakness, and myalgia since age 5 years, was admitted to the hospital. She was the first child of unrelated healthy parents. She was born uneventfully and was normal in psychomotor development. At age 2 years, she developed the first episode of generalized tonic-clonic seizure while she was sleeping. At age 4 years, she had the second episode of generalized tonic-clonic seizure when she was under general anesthesia for tonsillectomy, whose cause was thought to be hypoglycemia due to prolonged fasting. In both episodes, seizure was followed by strong limb pain. At age 5 years, she suffered from the first episode of syncope while climbing up stairs. She recovered after a few hours. One year later, she had the second syncopal attack after running 50 m, which was accompanied by subsequent limb muscle weakness and myalgia. Since then, similar episodes were repeated several times a year. For each bout, she first developed leg muscle weakness immediately after exercise, making her squat down, and gradually lost the consciousness. She recovered her consciousness after a few hours but always experienced strong myalgia in legs which lasted for several hours. Blood glucose level was not decreased during these attacks.

On admission, general physical examination revealed no abnormal finding. On neurological examination, she had mild proximal dominant muscle weakness and mildly limited dorsiflexion of both ankle joints. T1-weighted images of skeletal muscle MRI showed high signal intensities in gluteal and flexor muscles of the thigh, which were assessed to be fatty degeneration (Fig. 1). Systemic investigations including electrocardiography, echocardiography, stress cardiac catheterization, stress myocardial scintigraphy, brain imaging, electroencephalography, and screening tests for metabolic diseases revealed no abnormality except for a mild ischemic finding on exercise electrocardiography. Ischemic and non-ischemic forearm exercise tests [8] showed the lack of lactate elevation, raising a possibility of glycogen storage disease. A few months later, resting electrocardiography, 24-h holter monitoring and resting echocardiography were re-evaluated and again revealed normal findings.




Fig. 1. Muscle MRI, T2WI, axial. It shows high intensity in gluteus maximus and biceps femoris muscles.

3. Histological analysis of skeletal muscle

Muscle biopsy was performed from biceps brachii. Serial frozen sections were stained with hematoxylin and eosin, modified Gomori trichrome, and a battery of histochemical methods. The most striking finding was depletion of glycogen in all muscle fibers but not in the interstitium on periodic acid-schiff (PAS) staining (Fig. 2A). Phosphorylase activity was also deficient in all fibers (Fig. 2B). Mitochondria especially at the periphery of muscle fibers were prominent on modified Gomori trichrome (Fig. 2D). ATPase staining revealed type 2 fiber atrophy. Electron microscopic analysis showed mitochondrial proliferation at the periphery of muscle fibers with no notable intramitochondrial inclusions (Fig. 2E).

4. Biochemical and molecular analysis

Both the activity of *GYS1* and the amount of glycogen in the skeletal muscle were markedly reduced (Table 1). On western blotting, *GYS1* in the patient's skeletal muscle was undetectable (Fig. 2F). The *GYS1* gene sequence analysis revealed compound heterozygous mutation of




Fig. 2. Histological, genetic and protein analyses. Periodic acid-schiff (PAS) staining shows marked depletion of glycogen in muscle fibers but not in the interstitium (A). Phosphorylase activity is also deficient in all fibers (B). Hematoxylin and eosin staining shows mild fiber size variation (C). On modified Gomori trichrome, mitochondria are prominent especially at the margin of each muscle fiber (D). On electron microscopy (EM), mitochondria are increased in number at the periphery of muscle fibers (E). Bars represent 100 μm for histochemistry and 7 μm for EM. On western blotting using anti-GYS1 antibody (Abcam), GYS1 protein is absent in skeletal muscle from the patient (F). Sequence analysis for the *GYS1* gene reveals a compound heterozygous mutation of c.1230-2A > G and c.1810-2A > G (G). cDNA analysis showed insertion of intron 9 between exon 9 and 10 and 36-bp deletion from the beginning of exon 15 (H).

Table 1

Analyses of enzymatic activity and glycogen content. The activity of GYS and glycogen content in skeletal muscle were markedly reduced.

	Glycogen synthase (mol/min/mg)	UDPG-pyrophosphorylase (nmol/min/mg)	Glycogen contents (% of wet weight)
Patient	<i>0.9</i>	30.5	<i>0.03</i>
Control	42.0 \pm 11.2	31.2 \pm 3.5	0.94 \pm 0.55

Italicized values: lower than control range.

c.1230-2A > G in intron 9 and c.1810-2A > G in intron 14 (Fig. 2G). cDNA analysis confirmed the insertion of the full-length intron 9 between exons 9 and 10 and a 36-bp deletion in the beginning of exon 15 (Fig. 2H).

5. Clinical course after diagnosis

Upon the diagnosis of GSD0, exercise was strictly limited to avoid syncope resulted from glucose depletion. In

addition, oral intake of cornstarch (2 g/kg, every 6 h) was started to maintain blood sugar level. Her condition had been stable for 1 year after diagnosis. However, at age 12 years, she was found lying unconsciously on the stairs at her school. She had persistent asystole despite ambulance resuscitation. The blood glucose level in the emergency room was above 100 mg/dl.

6. Discussion

We identified the first Asian patient with muscle GSD0, who manifested recurrent episodes of syncope with subsequent muscle weakness and myalgia, and eventually developed cardiac arrest.

Findings in our patient seem to be similar to previous reports, but some differences indicated the possibility of another pathogenesis of the disease. Our patient repeatedly suffered from episodes of syncope. In contrast to two earlier reports, those patients never had syncope, although the last attack led to sudden death [6,7]. In support of this notion, most muscle glycogen synthase knock-out mice died soon after birth due to impaired cardiac function [8]. However, the pattern of loss of consciousness in our patient cannot be explained by simple cardiac dysfunction, as she lost her consciousness gradually after exercise and took hours to regain, which is different from typical cardiac syncope, usually showing sudden loss of consciousness and rapid recovery. Alternatively, defective glycogen synthesis in brain may be related to syncope, as *GYS1* is also expressed in brain, albeit not so much as in cardiac and skeletal muscles. Another possibility may be intermittent arrhythmia. However, electrocardiogram during the episode was never obtained. Further studies are necessary to answer this question.

On muscle pathology and electron microscopy, we found profound deficiency of glycogen in all muscle fibers accompanied by mitochondrial proliferation, which is similar to previous reports. The mitochondrial proliferation may reflect a compensatory mechanism for supplying ATP to glycogen-depleted muscles. Interestingly, phosphorylase activity on histochemistry seemed deficient. This is consistent with the fact that endogenous glycogen is used as a substrate of phosphorylase on histochemistry. Previous reports described the reduced number of type 2 fibers. In our patient, type 2 fiber atrophy, but not type 2 fiber deficiency, was seen. Although type 2 fiber atrophy is a nonspecific finding, this picture might also reflect the dysfunction of glycogen-dependent muscle fibers.

7. Conclusion

We identified the first Asian patient with muscle GSD0. In our patient, recurrent episodes of syncope and eventual sudden death may not be simply explained by cardiac dysfunction. Further studies are necessary to elucidate the mechanism of syncope in muscle GSD0 and to establish appropriate guideline of management for these patients to prevent sudden death.

Acknowledgments

The authors thank Ms. Goto and Ms. Ogawa (National Center of Neurology and Psychiatry) for technical assistance in mutation analysis. This work is supported by: a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science; Research on Psychiatric and Neurological Diseases and Mental Health, Research on Measures for Intractable Diseases, Health Labour Sciences Research Grant for Nervous and Mental Disorders (20B-12, 20B-13) from the Ministry of Health, Labor, and Welfare, and Intramural Research Grant (23-4, 23-5, 23-6) for Neurological and Psychiatric Disorders of NCNP.

References

- [1] Viskupic E, Cao Y, Zhang W, Cheng C, DePaoli-Roach AA, Roach PJ. *J Biol Chem* 1992;267:25759–63.
- [2] Pederson BA et al. Abnormal cardiac development in the absence of heart glycogen. *Mol Cell Biol* 2004;24:7179–87.
- [3] Moslemi AR, Lindberg C, Nilsson J, Tajsharghi H, Andersson B, Oldfors A. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. *N Eng J Med* 2010;362:1203–10.
- [4] Shulman GI, Rothman DI, Jue T, Stein P, DeFronzo PA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by ¹³C nuclear magnetic resonance spectroscopy. *N Eng J Med* 1990;322:223–8.
- [5] Orho M, Bosshard NU, Buist NR, Gitzelmann R, Aynsley-Green A, Blümel P, et al. Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. *J Clin Invest* 1998;102:507–15.
- [6] Kollberg G, Tulinius M, Gilljam T, Ostman-Smith I, Forsander G, Jotorp P, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. *N Engl J Med* 2007;357:1507–14.
- [7] Cameron JM, Levandovskiy V, MacKay N, Utgiker R, Ackerley C, Chiasson D, et al. Identification of a novel mutation in *GYS1* (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. *Mol Genet Metab* 2009;98:378–82.
- [8] Pederson BA, Cope CR, Schroeder JM, Smith NW, Irimia JM, Thurberg BL, et al. Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise. *J Biol Chem* 2005;280:17260–5.

Molecular Basis of Two-Exon Skipping (Exons 12 and 13) by c.1248+5g>a in *OXCT1* Gene: Study on Intermediates of *OXCT1* Transcripts in Fibroblasts

Tomohiro Hori,¹ Toshiyuki Fukao,^{1,2*} Keiko Murase,¹ Naomi Sakaguchi,¹ Cary O. Harding,³ and Naomi Kondo¹

¹Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Gifu, Japan; ²Medical Information Sciences Division, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan; ³Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon

Communicated by Peter H. Byers

Received 2 April 2012; accepted revised manuscript 30 November 2012.

Published online 21 December 2012 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22258

ABSTRACT: The molecular basis of simultaneous two-exon skipping induced by a splice-site mutation has yet to be completely explained. The splice donor site mutation c.1248+5g>a (IVS13) of the *OXCT1* gene resulted predominantly in skipping of exons 12 and 13 in fibroblasts from a patient (GS23) with succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency. We compared heteronuclear RNA (hnRNA) intermediates between controls' and GS23's fibroblasts. Our strategy was to use RT-PCR of hnRNA to detect the presence or absence of spliced exon clusters in RNA intermediates (SECRIs) comprising sequential exons. Our initial hypothesis was that a SECRi comprising exons 12 and 13 was formed first followed by skipping of this SECRi in GS23 cells. However, such a pathway was revealed to be not a major one. Hence, we compared the intron removal of SCOT transcript between controls and GS23. In controls, intron 11 was the last intron to be spliced and the removal of intron 12 was also rather slow and occurred after the removal of intron 13 in a major pathway. However, the mutation in GS23 cells resulted in retention of intron 13, thus causing the retention of introns 12 and 11. This "splicing paralysis" may be solved by skipping the whole intron 11–exon 12–intron 12–exon 13–mutated intron 13, resulting in skipping of exons 12 and 13.

Hum Mutat 34:473–480, 2013. © 2012 Wiley Periodicals, Inc.

KEY WORDS: two-exon skipping; splicing order; splice site; heteronuclear RNA; SCOT; succinyl-CoA:3-ketoacid CoA transferase

Introduction

Transcription of mRNA precursors by RNA polymerase II and their splicing by the spliceosome are essential steps in gene expres-

Additional Supporting Information may be found in the online version of this article.

*Correspondence to: Toshiyuki Fukao, Department of Pediatrics, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan. E-mail: toshi-gif@umin.net

Contract grant sponsors: Ministry of Health, Labor and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan.

sion. Moreover, splicing is cotranscriptional [Maniatis and Reed, 2002]. Splicing is thus ordered but not processive [Gudas et al. 1990; Kessler et al. 1993; Lang and Spritz 1987].

Most introns have conserved 5' (donor) and 3' (acceptor) sequences that flank the exons, a short polypyrimidine tract adjacent to the acceptor site, and a branch point sequence 18–40 nucleotides upstream from the acceptor dinucleotide [Berget, 1995; Hawkins, 1988]. Mutations in these sites can lead to exon skipping, short deletions, or insertions in the mature mRNA. It is difficult to predict the effects of splice-site mutations and understanding requires analysis of the various mRNA spliced products in cells that express the target gene. Mutations affecting splicing are a major fraction of disease-causing mutations in humans. The mechanisms whereby gene mutations result in aberrant splicing are mostly apparent from current exon-definition models of splicing [reviewed by Berget, 1995].

There are some examples where a single nucleotide substitution at such splice junctions causes the skipping of two exons [Fang et al., 2001; Haire et al., 1997; Hayashida et al., 1994; Schneider et al., 1993; Takahara et al., 2002]. The mechanisms for multiple skipping are not apparent from current exon- and intron-definition models of splicing [Takahara et al., 2002] and not well understood. The unusual occurrence of a two-exon skip may be explained by the order of intron removal in this region such that an intron is removed rapidly, in most transcripts, with respect to adjacent two introns, so that a large exon-like structure can then be skipped [Takahara et al., 2002]. In this article, we designate such an exon-like structure as a spliced exon cluster in RNA intermediates (SECRIs). Splicing order, therefore, may be an important factor in the understanding of outcomes of splice-site mutations and that multiple products are derived from different splicing pathways. Kessler et al. (1993) reported a method to determine the order of intron removal using RT-PCR, followed by several reports that determined the order of intron removal using this method [Attanasio et al., 2003; Schwarze et al., 1999; Takahara et al., 2002].

Succinyl-CoA:3-ketoacid CoA transferase (SCOT, gene symbol *OXCT1*, EC 2.8.3.5, MIM #601424), a mitochondrial homodimer essential for ketone body utilization, catalyzes the activation of acetoacetate to acetoacetyl-CoA in extrahepatic tissues [Mitchell and Fukao, 2001]. SCOT deficiency (MIM #245050), clinically characterized by episodes of severe ketoacidosis, is an autosomal recessive inborn error of metabolism, first described in 1972 [Tildon and Cornblath, 1972]. Since the first description of SCOT deficiency, fewer than 30 affected probands have been reported including personal communications [Baric et al., 2001; Berry et al., 2001; Cornblath et al., 1971; Fukao et al., 1996, 2000, 2004, 2006, 2007, 2010,

2011; Kassoovska-Bratinova et al., 1996; Longo et al., 2004; Merron and Akhtar, 2009; Niezen-Koning et al., 1997; Perez-Cerda et al., 1992; Pretorius et al., 1996; Rolland et al., 1998; Sakazaki et al., 1995; Snyderman et al., 1998; Song et al., 1998; Tildon and Cornblath, 1972; Yamada et al., 2007].

We describe herein the molecular basis of SCOT deficiency in a 7-month-old boy (GS23). We detected a homozygous gene mutation, c.1248+5g>a, and the simultaneous skipping of exons 12 and 13. We compared splicing order in GS23's fibroblasts with that of control cells, to understand the mechanism of two-exon skipping in GS23 cells.

Materials and Methods

Patients

The patient (GS23) was a male infant born to nonconsanguineous parents of Mexican ancestry. He suffered recurrent ketoacidotic episodes in association with intercurrent infection beginning at the age of 7 months. He was suspected to have SCOT deficiency because he had permanent ketosis. The diagnosis was confirmed by enzyme assay. This study was approved by the Ethical Committee of Gifu University School of Medicine. The parent's DNAs were not available for this study.

Fibroblasts and Enzyme Assay

Fibroblasts from GS23 and controls were cultured in Eagle's minimal essential medium containing 10% fetal calf serum (FCS). A SCOT assay was performed as described by Williamson et al. (1971), with modifications [Song et al., 1997]. Briefly, the assay mixture contained 30 μ M acetoacetyl-CoA and 50 mM sodium succinate in 50 mM Tris-HCl (pH 8.5), 10 mM MgCl₂, and 4 mM iodoacetamide, and SCOT activity was measured spectrophotometrically as a decrease of acetoacetyl-CoA absorption at 303 nm.

Immunoblot Analysis

Immunoblot analysis was performed as described by Fukao et al. (1997), using a mixture of antihuman SCOT antisera and antihuman mitochondrial acetoacetyl-CoA thiolase antisera as the first antibody and 30 μ g of fibroblast protein extract.

Mutation Screening at Genomic Level

Genomic DNA was purified using Sepa Gene kits (EIDIA, Tokyo, Japan) from GS23's fibroblasts. Mutation analysis was performed by PCR amplification of each exon and its boundaries (at least 18 bases from the exon/intron boundaries for both directions) with a pair of intronic primers, described in Supp. Table S1, followed by direct sequencing. Genomic sequence was obtained from GenBank NM 000436.3. The identified mutation was submitted to the Leiden Open Variation Database (www.lovd.nl/OXCT1).

Nonsense-Mediated mRNA Decay Inhibition

To determine whether any observed reduction of the transcript was due to nonsense-mediated mRNA decay (NMD) [Maquat, 2005], we inhibited NMD by fibroblasts with cycloheximide (CHX) (Sigma, St. Louis, MO), a general protein translation inhibitor. Fibroblasts were left untreated or cultured in the presence of 200 μ g/ml

CHX for 5 hr before RNA extraction. This analysis was performed as described by Hernan et al. (2011).

cDNA Analysis

Total RNA was isolated from fibroblasts using ISOGEN kits (Nippon Gene, Tokyo, Japan). Total RNA (5 μ g) was reverse transcribed in 20 μ l of 50 mM Tris-HCl pH 7.5, 75 mM KCl, 3 mM MgCl₂, 10 mM dithiothreitol, 0.5 mM dNTPs, 200 U of M-MLV reverse transcriptase (Life Tech., Rockville, MD) with a primer mixture including 5 pmol each of SCOT-specific antisense primer, SCOT 25 5'-c.1646CAATTATGATTATTGATGTCC-3', GAPDH-specific antisense primer, GAPDH3 5'-1040GTGCTCTTGCTGGGGCTG-3', and oligo dT primers. The above preparation was incubated at 37°C for 1 hr. One microliters of this cDNA solution served as a PCR template. The positions of the PCR primers were numbered in relation to the adenine of the initiation methionine codon, which was assigned position +1.

The full-coding sequence of SCOT cDNA was amplified (c.-4 - 1586).

Primer SCOT 42 (sense) 5'-c.4GAAGATGGCGGCTCTCAAA-3'

Primer SCOT 24 (antisense) 5'-c.1586AGCCTGGTACAAATATCCATA-3'

To evaluate the amount of total mRNA products, GAPDH cDNA was also amplified with the following sets of primers:

GAPDH1 (sense) 5'-c.4GGGAAGGTGAAGGTC-3'

GAPDH2 (antisense) 5'-c.1015AGGGGTCTTACTCCTTGGAG-3'

These cDNA sequences were obtained from GenBank accession number NM 002046.4 for GAPDH and NM 000436.3 for SCOT.

After 30 PCR cycles, amplified fragments were separated by electrophoresis on a 3.5% (w/v) polyacrylamide gel and a 1% (w/v) agarose gel, and extracted using a GeneClean II kit (BIO 101, Vista, CA). Sequences of amplified fragments were confirmed by direct sequencing.

Isolation of Nuclear RNA

Fibroblasts were grown to near confluence in 80 cm² flasks in DMEM with 10% FCS. The incubation was terminated by repeated rinsing with ice-cold 1 \times PBS to inhibit nuclear mRNA export. Nuclear and cytoplasmic fractions were separated by incubating the scraped cell pellets in a Nonidet P-40 buffer (10 mM Tris, pH 7.4; 10 mM NaCl; 3 mM MgCl₂; 0.5% Nonidet P-40) for 10 min on ice, followed by centrifugation for 5 min at 1,450 \times g, 4°C. The supernatant contained the cytoplasmic components. The nuclear pellet was stirred by pipetting 10 times, washed in the Nonidet P-40 buffer, and centrifuged for 5 min under the same conditions as described above. The supernatant was discarded, and the pellet was used as the nuclear fraction. Nuclear RNA was isolated from the nuclear fraction using ISOGEN kits (Nippon Gene). Nuclear RNA (10 μ g) was incubated in 50 μ l of 1 U deoxyribonuclease (RT Grade; Nippon Gene) at 37°C for 5 min, then a 5- μ l stop solution was added and it was inactivated at 70°C for 10 min.

Analysis of SECRI by RT-PCR

The isolated nuclear RNA contains a mixture of various stages of splicing intermediates. To investigate the order of intron removal or splicing order, we analyzed the presence or absence of various SECRI by RT-PCR. Our strategy was to first identify, using specific primer pairs, all possible SECRI of two adjacent exons (such

as exons 2–3 fusion), then to search for SECRIs comprising three sequential exons (such as exons 1–2–3 fusion), four sequential exons, and so on. For example, if intron 12 is spliced out before the removal of introns 11 and 13, a SECRI comprising exons 12 and 13 is predicted to be amplified by a sense primer in intron 11 and an antisense primer in intron 13.

We designed PCR primers as shown in Supp. Table S1. Sense primers, ex1F to in16F, were used for amplification of exon 1 to exon 17, respectively. Antisense primers, in1R to ex17R, were for amplification of exon 1 to exon 17, respectively. To initiate cDNA synthesis from nuclear RNA, we employed additional SCOT-specific antisense primers, labeled in2R' to ex17R', that were located downstream from in2R to ex17R, respectively. Three separate cDNA synthesis reactions were carried out using mixtures of either in2R', in3R', in4R', in5R', and in6R' primers, of in7R', in8R', in9R', in10R', and in11R' primers, or of in12R', in13R', in14R' in15R', in16R', and ex17R' primers. The cDNA products then served as templates for PCR detection of various SECRIs using in2R, in3R, in4R, in5R, and in6R antisense primers, in7R, in8R, in9R in10R, and in11R antisense primers, or in12R, in13R, in14R in15R, in16R, and ex17R antisense primers, respectively.

All primers listed in Supp. Table S1, except for ex1F, ex11F, ex12F, ex13F, ex13R, ex14R, ex15R, ex15R', ex17R, and ex17R', were complementary to intronic sequences. ex1F was placed upstream from the initiation codon on exon 1. ex17R and ex17R' were placed downstream from the termination codon on exon 17.

Nuclear RNA (2 μ g) was reverse transcribed in 20 μ l of 50 mM Tris-HCl pH 7.5, 75 mM KCl, 3 mM MgCl₂, 10 mM dithiothreitol, 0.5 mM dNTPs, the mixture of the above antisense primers (10 pmol each) and 200 U of M-MLV reverse transcriptase (Life Tech.) at 37°C for 1 hr. One microliter of this cDNA solution served as a PCR template. Specific exons were amplified using 30 pmol each of the above sense and antisense primers for 35 PCR cycles. Each cycle consisted of 1 min of denaturation at 94°C, 2 min of annealing at 60°C, and a 1-min extension at 72°C. The amplified fragments were detected following electrophoresis on a 2% (w/v) agarose gel and ethidium bromide staining. Sequences of amplified fragments were confirmed by direct sequencing.

Analysis of Intron Removal Around Exons 11–14

Fibroblasts from a control and from the patient were grown to near confluence in six-well tissue-culture plates in DMEM with 10% FCS. The medium was then replaced by serum-free DMEM, and 5 μ g/ml of Actinomycin D (Roche Diagnostics, Basel, Switzerland) was added to halt transcription. The incubation was terminated after 5, 10, 20, 40, or 60 min by adding 1 ml of ISOGEN solution. One well of each cell line was left untreated to serve as a baseline control. Total RNA using ISOGEN kit (Nippon Gene) from the different timepoints was treated with Deoxyribonuclease, as described above. cDNA synthesis reactions were carried out using a mixture of SCOT-specific antisense primers in13R', in14R', and ex15R' (Supp. Table S1). To check for residual genomic DNA in the RNA preparation, one PCR reaction was done without prior reverse transcription.

Results

Enzyme Assay and Immunoblot Analysis

SCOT activity in GS23's fibroblasts (0.4 ± 0.9 nmol/min/mg protein, $n = 7$) was less than 10% of SCOT activity in control fibroblasts (4.5 ± 1.2 nmol/min/mg protein, $n = 7$), whereas acetoacetyl-

CoA thiolase activity in the presence of potassium ion (9.4 ± 2.6 nmol/min/mg protein, $n = 7$) was similar to that of controls (8.0 ± 1.7 nmol/min/mg protein, $n = 7$). In immunoblot analysis, SCOT protein was not detected in GS23's fibroblasts, whereas SCOT protein was clearly detected in control fibroblasts (data not shown). These analyses thus confirmed SCOT deficiency in GS23.

Gene Mutations

Sequencing of the SCOT gene in GS23 revealed an apparent homozygosity for a G to A mutation at the fifth nucleotide of intron 13 (c.1248+5g>a) (Fig. 1A). No other mutations were detected by sequencing of all exons and the exon–intron boundaries.

cDNA Analysis

We first performed RT-PCR using total RNA with CHX-untreated fibroblasts. Amplification of the SCOT cDNA (c.-4 – 1586) from control fibroblasts produced a single fragment with the expected size of 1,590 bp (Fig. 1B, control CHX-, indicated by arrow 1). However, in GS23, there were two faint shorter fragments of approximately 1,450 bp (GS23 CHX-, indicated by arrow 2) and 1,100 bp (indicated by arrow 3). Sequence analysis of these fragments revealed that the 1,450 bp fragment (indicated by arrow 2) lacked exons 12 and 13 (Fig. 1C), whereas the 1,100 bp fragment lacked exons 8–13. Because skipping of exons 12 and 13 results in a frame-shift and skipping of exons 8–13 does not, we reperfomed RT-PCR using total RNA from CHX-treated and nontreated fibroblasts to confirm that the mRNA with skipping of exons 12 and 13 is a major transcript in GS23.

When we inhibited NMD by treating fibroblasts with CHX, the cDNA with skipping of exons 12 and 13 was amplified much more abundantly than the cDNA with exons 8–13 skipping in case of GS23 (Fig. 1B, GS23 CHX+), whereas no change was observed in the case of a control (Control CHX+). On the basis of this experiment, we concluded that the major transcript in GS23 had skipping of exons 12 and 13 and was subjected to NMD. On the contrary, mRNA with skipping of exons 8–13 is in-frame, and should be a minor transcript.

We considered that the mutation at the splice donor site of intron 13 (c.1248+5g>a) caused exons 12 and 13 skipping instead of solely exon 13 skipping. We tested a hypothesis that two exons were skipped because the upstream intron 12 was rapidly removed, similar to the model proposed by Takahara et al. (2002).

Analysis of RNA Intermediates Encompassing Exons 12 and 13

To test this hypothesis, we analyzed splicing of heteronuclear RNA (hnRNA) in GS23 and control fibroblasts. As shown in Figure 2, a fragment with exon 12–intron 12–exon 13 (intron 12 retained) was detected in both controls and GS23, but a SECRI comprising exons 12 and 13 was clearly identified in only the two control fibroblasts but hardly detected in GS23 fibroblasts. Amplification of hnRNA using primers specific to exons 11 and 14 yielded no product in control fibroblasts but did detect a SECRI comprising exons 11 and 14 lacking exons 12 and 13 (Fig. 2).

These results indicate that (1) the skipping of exons 12 and 13 in GS23 may not be associated with an initial fusion of exons 12 and 13; but that (2) this splice-site mutation may alter the order of intron removal in SCOT RNA processing.




Figure 1. Genomic DNA analysis and RT-PCR analysis. **A:** An apparently homozygous point mutation from G to A was found at the fifth nucleotide of intron 13 (c.1248+5g>a) in GS23 as indicated by the arrow. **B:** RT-PCR analysis using RNAs from CHX-treated and CHX-untreated fibroblasts. SCOT cDNA (c.-4 - 1586) was amplified and electrophoresed on a 3.5% (w/v) polyacrylamide gel. In a control, a fragment with the expected size of 1,590 bp (indicated by arrow 1) was clearly detected. In GS23, a fragment with the expected size was hardly detected; however, two shorter fragments with the size of ca. 1,450 bp (indicated by arrow 2) and 1,100 bp (indicated by arrow 3) were detected. Sequence analysis of GS23's fragments revealed that the longer fragment had exons 12 and 13 skipping and the shorter one had skipping of exons 8-13. CHX: cycloheximide. **C:** Exons 12 and 13 skipping identified in GS23's cDNA.

Determination of the Last Intron to be Spliced

Our strategy was to detect hnRNA-derived cDNAs that had a solitary intron, by definition, the last intron to be spliced; such molecules would be capable of being amplified with primers from that intron and a terminal exon, as described by Kessler et al. (1993). We first detected such cDNAs using the common sense primer in exon 1 (ex1F) and a series of antisense primers in introns 2-16 (in2R-in16R) and the antisense primer in exon 17 (ex17R). In control fibroblasts (Figs. 3A and 3C), SECRI comprising exons 1 and 2, exons 1-3, exons 1-7, exons 1-9, exons 1-11, and exons 1-17 were detected. Secondly, we used a common antisense primer on exon 17 (ex17R) and a series of sense primers from ex1F to in15F. In the two

controls, SECRI comprising exons 16 and 17, exons 15-17, exons 14-17, exons 13-17, exons 12-17, and exons 1-17 were detected. Intron 11 was the only possible solitary intron identified from both directions. These results suggested that the SECRI comprising exons 12-17 was ligated to the SECRI comprising exons 1-11 and that intron 11 removal was likely the final splicing event in controls. In addition, the amplification using a combination of in11F and ex17R produced a larger fragment including intron 12, as indicated by arrow 2 in Figure 3A, which suggested that the removal of intron 12 was also a late event. These findings are in accord with the result that no SECRI spanning exons 11-14 was amplified in controls (Fig. 2).

In the case of GS23 fibroblasts (Figs. 3B and 3D), the amplification pattern using the ex1F primer and a series of antisense primers from in2R to ex17R was similar to that of the control. However, the amplification pattern using the ex17R antisense primer and a series of sense primers from ex1F to in15F sense primers differed from that of controls. Several different pathways are possible and it is difficult to determine which pathway is the major one. Introns 7, 9, and 11 are possible last introns to be spliced in GS23 fibroblasts. In addition, a large sequence encompassing intron 11-exon 12-intron 12-exon 13-mutated intron 13 could also be spliced out lastly.

Detection of SECRI Flanked by Introns

We also amplified SECRI flanked by introns. Figures 3E and 3F showed all such SECRI detected by PCR (also see Supp. Fig. S1). In controls, SECRI in which intron 11 was spliced out were not detected and products in which intron 12 was retained were detected (Fig. 3E). In the case of GS23, SECRI in which mutated intron 13 was spliced out were not detected (Fig. 3F).

Comparison of Intron Removal Around Exons 11-14 Between Controls and GS23

According to the Kessler's original method [Kessler et al., 1993], several intron/exon primer pairs were used to amplify cDNA synthesized from total RNA from fibroblasts treated with Actinomycin D for different periods, although introns 11, 13, and 14 were too long to amplify intermediates including these introns (Fig. 4A).

Control fibroblasts

When we placed primers in exon 11 (ex11F) and intron 12 (in12R), no PCR products were amplified, as expected from the facts that intron 11 is too long (6,272 bp) to amplify and intron 11 is the last intron to be spliced in controls. When the primers were placed in intron 11 (in11F) and exon 13 (ex13R), the product that retained intron 12 and a SECRI in which intron 12 was spliced out were detected at 0 min. The former was no longer detectable at 60 min but the latter was still detected at 60 min. When primers were placed in exon 12 (ex12F) and intron 13 (in13R), the major product retained intron 12 and the minor product was a SECRI in which intron 12 was spliced out. Both disappeared by 60 min. When primers were placed in intron 12 (in12F) and exon 14 (ex14R), a SECRI in which intron 13 was spliced out was detected at 0 min and disappeared by 60 min. When primers were placed in exon 13 (ex13F) and intron 14 (in14R), a SECRI in which intron 13 was spliced out was clearly detected at 0 min and decreased with time. Lastly, when primers were placed in intron 13 (in13F) and exon 15